Verpasep

Biologicalexperimental

Clinical trial activity

6 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2002 (NCT00052897)

Timeline

2000s

  1. Jan 1, 2002

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bcg65-e7
  • hpv 16 e7/hsp65 vaccine
  • hpv e7 peptide epitope vaccine
  • hspe7
  • hspe7
  • hspe7
  • verpasep caltespen

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00493545Phase 1May 1, 2007Nventa Biopharmaceuticals Corporation
NCT00091130Phase 2Sep 1, 2004National Cancer Institute (NCI), University of California, Irvine
NCT00054041Phase 2Jun 1, 2004Gynecologic Oncology Group, National Cancer Institute (NCI)
NCT00075569Phase 2Mar 1, 2004National Cancer Institute (NCI), University of Connecticut, Yeshiva University
NCT00060099Phase 2May 1, 2003Harvard University, National Cancer Institute (NCI)
NCT00052897Phase 1/Phase 2 (Phase 2)Dec 1, 2002National Cancer Institute (NCI), University of California, San Francisco
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government5312002
Gynecologic Oncology GroupAcademic/Hospital1012004
Harvard UniversityAcademic/Hospital1112003
Nventa Biopharmaceuticals CorporationFor profit1112007
University of California, IrvineAcademic/Hospital1012004
University of California, San FranciscoAcademic/Hospital1012002
University of ConnecticutAcademic/Hospital1012004
Yeshiva UniversityAcademic/Hospital1112004
8 organizations
Page 1 / 1